Royalty Pharma plc - Class A Ordinary Shares (RPRX)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 14, 2026Investment Snapshot
- Trading 62% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 6.1% — below-average profitability
- Revenue growing at 5% annually
Royalty Pharma plc - Class A Ordinary Shares (RPRX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $23.3 billion . Key value metrics: P/E ratio 27.3, P/B ratio 2.04, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Royalty Pharma plc - Class A Ordinary Shares — Fundamental Analysis Summary
Royalty Pharma plc - Class A Ordinary Shares (RPRX) is currently trading 62% above its Graham Number of $32.92, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 27.3x.
On financial health, RPRX shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 6.1% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.69.
StockPik's composite Value Score for RPRX is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RPRX shows revenue growing at 5% year-over-year, with earnings declining at 10%.
RPRX pays a modest dividend yield of 1.7%.